LINZESS Drug Patent Profile

Which patents cover Linzess, and what generic alternatives are available?

Linzess is a drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in LINZESS is linaclotide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the linaclotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Linzess

Linzess was eligible for patent challenges on August 30, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2032. This may change due to patent challenges or generic licensing.

Annual sales in 2022 were $1.6bn, indicating a strong incentive for generic entry.

There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (linaclotide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for LINZESS

US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	19
Drug Prices:	Drug price information for LINZESS
Drug Sales Revenues:	Drug sales revenues for LINZESS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LINZESS
What excipients (inactive ingredients) are in LINZESS?	LINZESS excipients list
DailyMed Link:	LINZESS at DailyMed

See drug prices for LINZESS

See drug sales revenues for LINZESS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LINZESS

Constraining patent/regulatory exclusivity:

8,802,628*PED

NDA:

202811

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LINZESS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 2
National Cancer Institute (NCI)	Early Phase 1
RenJi Hospital	Phase 4

See all LINZESS clinical trials

Pharmacology for LINZESS

Drug Class	Guanylate Cyclase-C Agonist
Mechanism of Action	Guanylate Cyclase Activators

Paragraph IV (Patent) Challenges for LINZESS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LINZESS	Capsules	linaclotide	72 mcg	202811	1	2017-11-07
LINZESS	Capsules	linaclotide	145 mcg and 290 mcg	202811	4	2016-08-30

US Patents and Regulatory Information for LINZESS

LINZESS is protected by seven US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,802,628.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes	9,708,371*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	No	8,748,573*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes	10,675,325*PED				Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes	8,933,030*PED				Y

Expired US Patents for LINZESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012	8,110,553
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017	8,080,526
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017	7,371,727
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012	7,371,727
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012	7,704,947

EU/EMA Drug Approvals for LINZESS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Constella	linaclotide	EMEA/H/C/002490Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.	Authorised	no	no	no	2012-11-26

International Patents for LINZESS

When does loss-of-exclusivity occur for LINZESS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Paraguay

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LINZESS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E365174
Austria	E477268
Australia	2004210161	Methods and compositions for the treatment of gastrointestinal disorders
Australia	2005222387	Methods and compositions for the treatment of gastrointestinal disorders
Australia	2009235993	Methods and compositions for the treatment of gastrointestinal disorders

Supplementary Protection Certificates for LINZESS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1594517	300593	Netherlands		PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121128
1594517	C300593	Netherlands		PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
1594517	CA 2013 00026	Denmark
1594517	PA2013013	Lithuania		PRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
1594517	92200	Luxembourg		PRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUI-CI, PROTEGE PAR LE BREVET DE BASE, Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/12/801/001-004 20121126

LINZESS (linaclotide) market dynamics and financial trajectory: exclusivity, competitive threats, and revenue outlook

Last updated: July 22, 2026

LINZESS (linaclotide) has shifted from growth to a mature, price-and-volume dynamic shaped by chronic constipation and IBS-C prescribing, payer controls, and branded competition risk from generic linaclotide once patent and exclusivity barriers clear. The near-term financial trajectory is driven by net price realization, plan coverage, and dispensing trends in constipation and IBS indications while the longer-term trajectory hinges on generic entry timing versus patent estate strength and any Orange Book-listed method/formulation coverage.

What patents protect LINZESS (linaclotide) and how does the patent estate shape generic entry risk?

Short answer: LINZESS’s generic entry risk is governed by (1) listed Orange Book patents tied to drug substance, formulation, and method-of-use and (2) enforceable exclusivity periods for the FDA-approved product. Patent expiry timing determines the first permissible generic launch date and whether Paragraph IV challenges can accelerate entry.

LINZESS patent estate: what categories usually gate entry

For small-molecule oral products like linaclotide, the Orange Book portfolio typically concentrates in:

• Drug substance or crystalline form/salt-related claims (active ingredient manufacturing and solid-state)
• Formulation claims for capsule composition and release characteristics
• Method-of-use claims for indications such as IBS-C and chronic idiopathic constipation (CIC)
• Possibly manufacturing-process claims

Market impact: If method-of-use and formulation patents remain listed and enforceable, generic filers may face “skinny label” carve-out exposure that can limit competitive effect even after legal entry.

How to interpret “Orange Book status” for market dynamics

• If only drug substance/formulation patents remain, generics can often launch with the same label sooner or with limited label carve-outs.
• If method-of-use patents persist for IBS-C/CIC, payers and prescribers may continue to associate LINZESS with the full indicated population, reducing generic substitution velocity.

Litigation and Paragraph IV cadence: why it matters for revenue trajectory

• A Paragraph IV filing triggers discovery, injunction risk, and potential settlement timing that can move generic launch windows by years.
• For mature products, the biggest revenue inflection usually comes from the first FDA-approved generic entrant that is therapeutically interchangeable at the formulary level.

When does LINZESS lose exclusivity and what are the practical launch windows for generics?

Short answer: Generic launch timing depends on the last expiring Orange Book patent (including any pediatric exclusivity and listed FDA exclusivity) plus any patent-sunset litigation outcomes such as settlements.

Exclusivity vs. patent expiry: the market timeline investors model

A typical decision tree:

1. Earliest possible date based on statutory exclusivity (if any) and drug approval timing.
2. Last expiring Orange Book patent date for the relevant label.
3. Patent litigation and settlement terms that define launch permission.

Market impact: Even when legal barriers fall, payer and pharmacy channel switching can lag by quarters due to:

• contract renegotiations
• pharmacy benefit manager (PBM) switching cycles
• prescriber persistence for chronic GI therapies

What drives the “first meaningful” revenue decline after generic entry

• Gross-to-net deterioration from payer rebates and competitive pressure
• Coverage tightening around alternative low-cost options
• Loss of formulary position in IBS-C and CIC categories
• Dispensing shift from brand to generic and/or therapeutic alternatives (separate from interchangeability)

How many patents cover LINZESS formulations and delivery characteristics, and why does that affect payer switching?

Short answer: Formulation and manufacturing-related patents affect the substitutability profile, but the more direct lever on payer switching is label coverage and interchangeability status. If formulation barriers force slower entry or require carve-outs, market switching typically accelerates later.

Formulation patent clusters that matter commercially

• Capsule composition and excipient blends
• Dosage release profiles that support GI tolerability and efficacy
• Solid-state forms tied to stability and manufacturing consistency

Market impact: Payers respond more quickly when generics can maintain the same label. If interchangeability is delayed, LINZESS pricing power usually persists longer than investors expect.

What formulation patent outcomes mean for net sales

• If generic entry is legally delayed: net sales tend to track closer to volume growth minus pricing pressure.
• If generic entry occurs with full label: net sales decline usually steepens in the year of initial generic uptake.
• If generic entry occurs with label restrictions: brand retention can extend, and net sales decline can be slower.

Which companies are challenging LINZESS and what is the impact of Paragraph IV litigation on revenue?

Short answer: Paragraph IV challenges determine both legal timing and settlement leverage. For LINZESS, the financial trajectory depends on whether challenges led to authorized generic launch, settlements permitting early entry, or court injunction outcomes that extend brand duration.

How litigation affects the commercial path

• Successful brand enforcement postpones generic entry and preserves higher gross-to-net.
• Settlements can allow an “early entry” generic at a date that is earlier than the last patent expiry.
• Authorized generics can accelerate market share loss even when branded product remains on formulary.

Market impact: For mature branded GI products, each month of delayed generic entry can materially shift annual revenue forecasts because switching costs reset at contract renewals and PBM cycles.

What is the Orange Book status of LINZESS (linaclotide) and what does that mean for FDA substitution?

Short answer: The Orange Book ties listed patents to the approved NDA product. When patents covering the labeled indication are still listed, generic substitution and therapeutic equivalence can be constrained by label carve-out needs and litigation posture.

Orange Book listings and practical substitution

• Orange Book-listed patents guide FDA’s approval and generic labeling requirements during Paragraph IV and settlement periods.
• If patents are narrow to a specific strength or dosage form, switching can occur unevenly across dose strengths.

Market impact: For LINZESS, the market usually bifurcates by strength and indication usage patterns. If generic entry is enabled for only some strengths, the overall decline can be partially buffered.

How does LINZESS compete against alternative chronic constipation and IBS-C therapies, including generics and other drug classes?

Short answer: LINZESS competes in GI pain and constipation-related symptom control against:

• other prescription GI agents used in IBS-C and chronic constipation
• over-the-counter laxatives and motility agents that drive non-prescription substitution in some payers
• branded and generic competitors that compete on formulary tiering and rebate structures

Competitive pressure channels that drive financial trajectory

1. Formulary tiering: preference for lower-cost agents changes prescription volume.
2. Prior authorization (PA): PA and step therapy slow patient starts and refill cadence.
3. Patient switching: chronic tolerability and symptom response determine persistence after a formulary change.
4. Dose availability: adherence depends on dosing convenience and GI tolerability.

Market impact: Even in the absence of generic linaclotide entry, formulary pressure can drive net sales compression. With generic entry, the combined effect usually accelerates.

What dosage forms and indications drive LINZESS net sales, and where are the incremental growth levers?

Short answer: LINZESS’s sales are primarily driven by chronic constipation and IBS-C populations using its approved oral capsule regimen. Incremental levers are typically new patient starts (payer approvals) and persistence, not new formulation adoption.

Commercial levers by indication

• Chronic idiopathic constipation (CIC): persistence is a key driver; discontinuation rates after early intolerance typically cap upside.
• IBS-C: symptom-based prescribing can lead to churn if payers tighten access or if competitors offer lower access friction.

How payer policy translates into financial outcomes

• PA approvals reduce “time to therapy,” sustaining new starts.
• Step therapy increases off-label or OTC pathways that siphon volume.
• Contracting changes can shift channel demand before FDA generic entry.

Market impact: This is how LINZESS can show stable revenue for a period even while patent risk rises.

How strong is LINZESS’s patent estate versus biosimilar or biologic-style risk, and why does the drug class matter?

Short answer: LINZESS is a small-molecule peptide-like agent (linaclotide) and does not face biosimilar pathways. The relevant competitive risk is chemical/generic entry plus any formulation or method-of-use barriers.

Why this matters

• Biosimilar timing and patent complexity typical of biologics are not applicable.
• The dominant legal question is whether generic filers can use FDA approval pathways without infringing Orange Book-listed patents tied to the approved claims.

Market impact: The risk profile is more binary around patent expiry and litigation outcome than the multi-step biosimilar competitive cycle.

What generic entry risks exist for LINZESS and what manufacturing/IP barriers could slow down substitution?

Short answer: Generic entry risks concentrate on:

• patent carve-out requirements for method-of-use
• any remaining formulation solid-state or release-characteristic barriers
• litigation outcomes that can delay approval or entry dates

Manufacturing/IP barriers that influence adoption

• bioequivalence and stability consistency for chronic GI use
• quality and supply chain readiness
• label compatibility for pharmacy claims processing

Market impact: Even with legal approval, adoption depends on supply, rebates, and contracts. This can produce a phased revenue decline rather than an immediate collapse.

How does LINZESS compare with competing agents on expected gross-to-net pressure and forecast volatility?

Short answer: LINZESS forecast volatility usually increases as generic entry approaches and when formulary changes compress gross-to-net. Competitive GI agents can also introduce volatility through PA policy shifts.

What to expect in net price realization

• Brand-only periods: net price declines mainly from standard contracting and competitive rebate pressure.
• Patent cliff periods: gross-to-net drops faster as PBMs demand larger rebates for any remaining exclusivity.
• Generic entry periods: additional net price compression from market-share loss and competitive contracting.

Market impact: The key financial question for LINZESS is not whether a competitor exists, but whether generic substitution is legally and contractually enabled quickly.

Key takeaways

• LINZESS’s financial trajectory is dominated by net price realization and formulary persistence in chronic constipation and IBS-C, with generic linaclotide entry risk as the primary longer-term shock factor.
• Patent and Orange Book status determine if generics can launch with full label coverage or only via carve-outs that slow market share erosion.
• Paragraph IV litigation outcomes and any settlements are the main timing drivers for when revenue declines can accelerate.
• Competitive GI landscape and payer controls can compress net sales even before generic entry, creating “early” revenue pressure that investors should not attribute solely to patent expiry.

FAQs

1. Does LINZESS face biosimilar competition risk?
   No biosimilar pathway applies to linaclotide; the key pathway risk is chemical generic substitution under FDA generic approval frameworks.

2. How do prior authorization and step therapy affect LINZESS revenue?
   They can reduce new patient starts and increase time to therapy, lowering volume and stretching conversions to persistence.

3. What typically happens to LINZESS net sales at the first generic launch?
   Net sales usually decline faster in the year of initial uptake due to formulary pressure, rebate renegotiations, and channel switching.

4. Can generics launch with a label carve-out and still compete heavily?
   Yes, but competitive effectiveness depends on whether the carve-out includes the most-used indication and strength for prescriptions in the PBM’s formulary design.

5. What is the main driver of LINZESS forecast risk for investors?
   The timing and scope of generic availability constrained by Orange Book patents and litigation outcomes, coupled with near-term payer net price movements.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. Drug Approval Package: LINZESS (linaclotide) NDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. Drugs@FDA. LINZESS (linaclotide). https://www.accessdata.fda.gov/scripts/cder/daf/

DrugChatter Q&A for LINZESS

When will the patent expire on linzess in canada?
Linzess 72 mcg price?
Linzess 145 mcg price?
When will linzess go generic?
Linzess strengths?